CEL-SCI Corporation (CVM)
NYSEAMERICAN: CVM · Real-Time Price · USD
7.90
-0.45 (-5.39%)
Aug 14, 2025, 11:21 AM - Market open
CEL-SCI Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
43
Market Cap
53.89M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
CVM News
- 53 minutes ago - CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results - Business Wire
- 1 day ago - CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline - Business Wire
- 4 weeks ago - CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules - Business Wire
- 4 weeks ago - CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules - Business Wire
- 4 weeks ago - CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer - Business Wire
- 2 months ago - FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients - Business Wire
- 2 months ago - CEL-SCI Announces Closing of Public Offering - Business Wire
- 3 months ago - CEL-SCI Announces Pricing of Public Offering - Business Wire